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Background: Respiratory syncytial virus (RSV) is the main cause of lower respiratory tract illness in children
worldwide. Molecular analyses show two distinct RSV groups (A and B) that comprise different genotypes. This
variability contributes to the capacity of RSV to cause yearly outbreaks. These RSV genotypes circulate within the
community and within hospital wards. RSV is currently the leading cause of nosocomial respiratory tract infections
in pediatric populations. The aim of this study was to evaluate the G protein gene diversity of RSV amplicons.
Methods: Nasopharyngeal aspirate samples were collected from children with nosocomial or community-acquired
infections. Sixty-three RSV samples (21 nosocomial and 42 community-acquired) were evaluated and classified as
RSV-A or RSV-B by real-time PCR. Sequencing of the second variable region of the G protein gene was performed
to establish RSV phylogenetics.
Results: We observed co-circulation of RSV-A and RSV-B, with RSV-A as the predominant group. All nosocomial and
community-acquired RSV-A samples were from the same phylogenetic group, comprising the NA1 genotype, and
all RSV-B samples (nosocomial and community-acquired) were of the BA4 genotype. Therefore, in both RSV groups
(nosocomial and community-acquired), the isolates belonged to only one genotype in circulation.
Conclusions: This is the first study to describe circulation of the NA1 RSV genotype in Brazil. Furthermore, this
study showed that the BA4 genotype remains in circulation. Deciphering worldwide RSV genetic variability will aid
vaccine design and development.
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Table 1 Characteristics of patients with hospital-and
community-acquired RSV infections treated at Hospital
de Clínicas de Porto Alegre, 2010
Characteristics Patients p-value
Hospital-acquired
infection (n = 21)
Community-acquired
infection (n = 42)
Mean age,
months [range]
15 [2-94] 9 [3-61] 0.013*
Mean length of
stay, days [range]
26.09 [2-73] 10.28 [0.6-71] 0.015*
Deaths 3 1 0.104
RSV-A infection 15 30




Age and length of stay were analyzed using the Mann-Whitney U test, and
number of deaths, using Fisher’s exact test.
*p-value <0.05.
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The respiratory syncytial virus (RSV) is considered the
leading cause of lower respiratory tract infections in chil-
dren worldwide [1,2]. RSV also infects adults and is a
major pathogen in older adults and immunocompromised
individuals [3]. RSV strains are separated into two major
groups (A and B) on the basis of antigenic and genetic
variability. The main differences are found in the attach-
ment glycoprotein G. RSV G protein interacts with host
cell receptors, is a target for neutralizing antibodies, and is
highly variable [4]. G protein variability is greater than that
of other RSV proteins, both between and within the RSV-
A and B groups. Molecular analysis of the second variable
region in the G protein has been used to characterize RSV
genotypes [5,6]. This variability might contribute to the
ability of the virus to cause yearly outbreaks [6,7].
RSV exhibits clear seasonality. Outbreaks occur in the
late fall and winter in temperate regions, and during ex-
tended periods related to rainy seasons in tropical regions
[8-10]. RSV-A and B genotypes show complex fluctuating
dynamics. They may co-circulate during a given season,
with one or two dominant genotypes that are then re-
placed in consecutive years [11-13]. These genotypes cir-
culate within the community and within hospital wards.
Consequently, nosocomial infection by RSV is observed
every year. RSV is the leading cause of nosocomial respira-
tory infections in pediatric populations. This virus is a
particular hazard for premature infants, infants with con-
genital heart disease or bronchopulmonary dysplasia, and
infants and children that are immunodeficient [14,15].
Nosocomial RSV outbreaks can cause severe morbidity
and mortality in infants, and carry a substantial financial
burden [16-18]. Palivizumab is a humanized monoclonal
antibody that is currently recommended as prophylaxis
for certain patient groups at risk of severe RSV infection
[18]. However, it is too expensive for wide-range use in de-
veloping countries such as Brazil [19].
Despite its pathogenic importance, there is no effective
vaccine against RSV [20]. Future development of vac-
cines or pharmacotherapy against RSV requires further
understanding of the genetic composition of viral strains
prevalent in a target population. The aim of the present
study was to evaluate the genetic diversity of the G pro-
tein gene in RSV samples collected from young children
with nosocomial or community-acquired infections in
Southern Brazil.
Results
Real-time PCR (RT-PCR) results confirmed the presence
of both RSV-A and RSV-B groups in the samples (21 from
nosocomial RSV patients and 42 from community-
acquired RSV patients). RSV-A was the predominant
group in both nosocomial and community-acquired
samples. Three cases of RSV-A/B co-infection weredetected, in two nosocomial samples and one community-
acquired sample. Patients with nosocomial RSV infections
were older and had longer hospital stays (Table 1).
We were able to obtain 56 sequences (40 RSV-A and 16
RSV-B) for phylogenetic analyses. Seven samples showed
no amplification or low-quality sequencing. Samples with-
out amplification may have degraded RNA, and those with
low-quality sequencing could be affected by non-specific
amplifications. Consequently, these samples were not con-
sidered for the phylogenetic analysis.
All RSV-A sequences (40 sequences), whether nosoco-
mial or community-acquired, were grouped with the NA1
genotype sequences. This phylogenetic branch, compris-
ing sequences from NA1 isolates and POA samples, pre-
sented a bootstrap value of 82% and was clearly distinct
from other genotypes (Figure 1). Moreover, the calculated
intra-genotype p-distance showed a high similarity be-
tween RSV-A POA sequences and the NA1 genotype
(Table 2).
Sixteen RSV-B sequences (nosocomial and community-
acquired) were grouped with the BA4 genotype sequences.
This phylogenetic branch, comprising sequences from
BA4 isolates and POA samples, is shown in Figure 1.
Therefore, all POA isolates had the 60-nucleotide duplica-
tion within the G gene originally reported in BA strains
[21]. Calculated p-distances showed intra-genotype simi-
larity and inter-genotype diversity among the RSV-B se-
quences (Table 2).Discussion
RSV is recognized as the leading cause of respiratory
tract illness in children and is a major nosocomial
pathogen. We evaluated RSV genetic variability in naso-
pharyngeal aspirate samples taken from children with
Figure 1 Phylogenetic trees for RSV-A (A) and RSV-B (B) nucleotide sequences based on the second variable region of the G protein,
using the neighbor-joining method and MEGA version 5.05. Reference strains (AF013254 for group A and AY911262 for group B) were used
as outgroup sequences in the tree. Scale bars show that the proportion of nucleotide substitutions and numbers at each branch are bootstrap
values determined from 1,000 iterations. Only bootstrap values with > 70% significance are shown. In phylogenetic tree for RSV-A (A)–sequences
identical to POA/193C/10 were POA/336H/10 and POA/344H/10; sequences identical to POA/66C/10 were POA/335C/10 and POA/312H/10;
sequence identical to POA/45A-H/10 was POA/96H/10; sequences identical to POA/15H/10 were POA/169H/10, POA187C/10, POA/166H/10,
POA144C/10, POA/136C/10, POA/124C/10, POA/106C/10, POA/62C/10, POA/18C/10, POA/1C/10, POA/203H/10, POA/229C/10, POA/254H/10,
POA/278C/10, POA/300C/10, POA/316C/10, POA/354C/10, POA/359H/10 and POA/33H/10; sequence identical to POA/155C/10 was POA171C/10;
sequences identical to POA/63H/10 were POA/114H/10, POA/179C/10 and POA/211C/10. In phylogenetic tree for RSV-B (B)–sequence identical to
POA/59C/10 was POA/121C/10; sequences identical to POA/16H/10 were POA/73H/10, POA/56H/10 and POA/57H/10.
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a large hospital in southern Brazil during 2010. The
patients with nosocomial RSV infection were character-
ized by prolonged hospital stays and increased mortality
(Table 1). Increased risk of severe RSV infection is usu-
ally associated with clinical conditions such asprematurity, chronic lung disease, congenital heart dis-
ease, and immunosuppression [1,14]. These same condi-
tions are common among children with prolonged
hospital stays [15].
RSV-A was the predominant group in both nosoco-
mial (15/21 or 71.43%) and community-acquired (30/42
Table 2 Pairwise nucleotide distances (p-distances),
intra-genotype and inter-genotype, for RSV-A (NA1) and
RSV-B (BA4) isolates
Subgroup Genotypes Intra-genotype Inter-genotype
(neighbor cluster)
RSV-A NA1 0.013 0.053 (NA1 × NA2)
RSV-B BA4 0.037 0.040 (BA4 × BA2)
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infection (4.76%) were observed. In previous RSV stud-
ies, co-circulation of groups A and B within the same
population has been described during epidemic periods,
and with different predominance patterns [12,22]. There
have been reports of co-circulation of the RSV-A and
RSV-B groups in different years, including in Brazilian
populations; however, most sequences have belonged to
the RSV-A group [23-25]. Shifts in predominance of par-
ticular circulating RSV groups within a given time inter-
val have also been described [21,26,27]. These shifts
appear to correlate, at least in part, with G-protein gene
variability [22]. However, as we collected samples only
during one epidemic period for the present study, con-
siderations about epidemiological patterns are restricted.
Only one RSV-A genotype was found circulating within
the study sample. It showed high similarities with the pre-
viously identified NA1 genotype isolated from Japan [12].
All RSV-A POA sequences (nosocomial and community-
acquired) were grouped with this genotype in a phylogen-
etic branch which presented a bootstrap value of 82%.
The p-distance calculated among these sequences was
low, demonstrating homogeneity among samples. This is
the first study to describe circulation of the Japanese NA1
genotype in Brazil. One could speculate that the introduc-
tion of this genotype to Brazil was probably recent and
that it became predominant in the Porto Alegre area.
Peret and colleagues have hypothesized that a constant
shift in predominant genotypes affects protective immun-
ity, allowing for more efficient virus transmission and
pathogenicity. Therefore, new RSV strains can be intro-
duced into a given population, but local factors such as
strain-specific immunity will determine which strains will
circulate successfully and cause outbreak [5].
We found only one circulating RSV-B group genotype
in southern Brazil during 2010: BA4. This genotype has
been previously described [21]. The phylogenetic branch
grouped many sequences, and the p-distance also indi-
cated some variability within this phylogenetic group
(p-distance = 0.037). However, all RSV-B POA genotypes
were grouped with the BA genotypes. The first BA geno-
type was described in Buenos Aires (Argentina) in 1999,
and harbors a 60-nucleotide duplication within the G
protein gene [28]. It has also been reported in Europe
and Asia [12,29,30]. The rapid and worldwide spread ofthe BA genotype implies that it may have a selective
advantage over other circulating strains [31]. However,
there may be mutations elsewhere in the genome that
confer more efficient replication when compared with
other RSV-B genotypes. Indeed, RSV (both RSV-A and
RSV-B groups) exhibits rapid evolutionary rates [21],
which might justify the emergence of many different ge-
notypes and variability within genotypes as well. The BA4
genotype has circulated worldwide for years and exhibits a
high mutation rate; therefore, many BA4 variants could be
generated.
In summary, this study evaluated the genetic diversity
of RSV within a patient cohort. To our knowledge, this
is the first time that circulation of the RSV-A NA1 geno-
type has been confirmed in Brazil. In addition, we report
circulation of the BA4 genotype during 2010. A better
understanding of RSV molecular epidemiology will be es-
sential for development of vaccines and antiviral pharma-
cotherapy against RSV infection. Currently, palivizumab is
recommended as a preventive measure in high-risk set-
tings. Unfortunately, this agent is too costly for use in de-
veloping countries [19]. Therefore, the development of an
efficient vaccine should remain a high priority in man-
aging RSV infection.Methods
Patients
Twenty-one pediatric patients were diagnosed with noso-
comial RSV infections at Hospital de Clínicas de Porto
Alegre, a tertiary referral center in southern Brazil, in
2010. Diagnostic criteria for nosocomially infected pa-
tients included absence of respiratory symptoms at the
time of hospital admission and detection of RSV by indir-
ect immunofluorescence in nasopharyngeal aspirate sam-
ples within 7 days of admission [14]. These 21 patients
account for all nosocomial RSV infections that occurred
in 2010. Furthermore, nasopharyngeal aspirate samples
from 42 pediatric patients with community-acquired RSV
infection were also analyzed. These patients were admitted
to the same ward as the nosocomially infected patients
1 week before or after their admission. Community-
acquired RSV patients stayed at the hospital for least
3 days.
All nasopharyngeal aspirate samples were obtained for
clinical purposes as part of standard care. The study
protocol was approved by the Institutional Review Board
of Hospital de Clínicas de Porto Alegre.Statistical analysis
Differences between the two groups (patients with
hospital-and community-acquired RSV infections) were
analyzed using the Mann-Whitney U test (age and length
of hospital stay) or Fisher’s exact test (number of deaths).
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statistical analyses were performed in SPSS 14.0.
Sample handling and nucleotide sequencing
Nasopharyngeal aspirate samples were collected in
phosphate-buffered saline (PBS) and frozen at −80°C
until RNA extraction. The samples were named according
to the city of origin (e.g. Porto Alegre–POA), number, and
infection setting (nosocomial, H; community-acquired, C).
RNA from a 140-μL aliquot of each sample was extracted
with a QIAamp Viral RNA Mini Kit (Qiagen, Valencia,
CA, USA), according to the manufacturer’s instructions.
RSV-positive samples were classified as RSV-A or RSV-
B by group-specific real-time PCR, as described previ-
ously [32].
For nucleotide sequencing, RT-PCR was performed on
extracted RNA using primers GAAGTGTTCAACTTTG
TACC/ CAACTCCATTGTTATTTGCC for RSV-A and
AAGATGATTACCATTTTGAAGT/CAACTCCATTGT
TATTTGCC for RSV-B, under previously described amp-
lification conditions [5]. We amplified the second variable
region of the G gene, including the C-terminal region of
protein G. PCR products were purified using a PureLink
PCR Purification kit (Invitrogen, Carlsbad, CA, USA).
Both strands were sequenced in an ABI 3500 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA)
using the BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA, USA).
Phylogenetic analyses
Sequences were assembled using BioNumerics software
version 6.0 and aligned with ClustalW. All RSV sequences
analyzed covering fragments beginning on nucleotide 615
until the end of the G gene. Phylogenetic analyses were
performed with MEGA 5.05 software [33], using the
neighbor-joining method and bootstrap analysis (1,000
replicates). Reference sequences for RSV-A and RSV-B
strains originating from the United States [6], Uruguay
and Argentina [21,34-36], Brazil [23-25], South Africa
[37], Kenya [26], New Zealand [38], Japan [7,12,39],
Canada [40], China [41] and Belgium [29] were obtained
from GenBank.
Pairwise nucleotide distances (p-distances), the num-
ber of pairwise nucleotide differences divided by the
total number of nucleotides in the sequenced segment,
were calculated using MEGA 5.05 [33]. A lower p-distance
indicated a greater similarity in compared sequences. To
improve the distribution and appearance of the phylogen-
etic tree, only unique sequences are shown (Figure 1).
Nucleotide sequence accession numbers
The GenBank accession numbers of the nucleotide se-
quences obtained in the present study are: JX524454 toJX524456; JX568889 to JX568900; JX627410 to JX627433;
and JX678714 to JX678729.
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